A U.S. Post-Approval Study of the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System.
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Boston Scientific Corporation
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Mar 2015 Planned End Date changed from 1 May 2017 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 08 May 2012 Planned End Date changed from 1 Oct 2017 to 1 May 2017 as reported by ClinicalTrials.gov.